In SLE patients, the cAMP responsive element modulator-α (CREMα), a transcriptional repressor of the IL-2 promoter, is hyperactive, resulting in silencing of IL-2 and reduced FOXP3 expression (164). Here, FOXP3 is linked to systemic lupus erythematosus.